Brain Cancer

Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multifo
Glioblastoma Multiforme (GBM) is almost inevitably a fatal tumor of the brain with most individuals dying within 1 year of diagnosis.

Los Angeles, CA 90048
USA
Modes of resistance to anti-angiogenic therapy
Angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signalling pathways are affording demonstrable therapeutic efficacy in mouse models of cancer and in an increasing number of human cancers.

San Francisco, CA 94143
USA
Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
Cancer vaccine trials have failed to yield robust immune-correlated clinical improvements as observed in animal models, fueling controversy over the utility of human cancer vaccines.

Los Angeles, CA
USA
Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells
To improve the efficacy and selectivity of virotherapy for malignant glioma, we designed a strategy to amplify adenoviral replication in conjunction with radiotherapy using a radioinducible promoter.

Chicago, IL
USA
Merlin is a potent inhibitor of glioma growth
Neurofibromatosis 2 (NF2) is an inherited cancer syndrome in which affected individuals develop nervous system tumors, including schwannomas, meningiomas, and ependymomas.

New York, NY 10029
USA
Temozolomide preferentially depletes cancer stem cells in glioblastoma
The prognosis of patients suffering from glioblastoma (GBM) is dismal despite multimodal therapy.

Regensburg, Germany
Germany
Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase me
A new adjuvant therapy, individual adjuvant therapy (IAT), which is individualized according to the results of real-time reverse-transcription polymerase chain-reaction (RT-PCR) for O6-methylguanine-DNA methyltransferase (MGMT), was used to treat malignant gliomas.

Ibaraki, 313-8511
Japan
Somatic alterations in brain tumors
Mutations in TP53 and RB1 have been shown to participate in the development of malignant brain tumors.

Cleveland, OH 44106
USA
Medulloblastoma: what is the role of molecular genetics?
Among pediatric malignancies, medulloblastoma (MB) is one of the most common malignant tumors of the CNS.
Avenue Molière - 67098

France
Molecular predictors in glioblastoma: toward personalized therapy
Recent therapeutic advances have improved standard treatment for patients with newly diagnosed glioblastoma.
1515 Holcombe Blvd, Unit 431
Houston, TX 77030
USA